Latest Life Stem Genetics Inc. (LIFS) Headlines
Post# of 5
Life Stem Genetics Inc partners with American CryoStem for patient's adipose tissue sample storage
M2 - Mon Nov 25, 4:26AM CST
Healthcare company Life Stem Genetics Inc (OTC BB:LIFS) reported on Friday the launch of a strategic collaborative agreement for the long term storage of their patient's adipose tissue sample.
Life Stem Genetics Announces Collaborative Agreement with American CryoStem
Business Wire - Fri Nov 22, 7:30AM CST
Life Stem Genetics, Inc. (OTCBB:LIFS) announced today a strategic collaborative agreement with American CryoStem Corporation, (OTCBB:CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries.
Life Stem Genetics Announces the Closing of Its Previously Announced $1 Million Private Placement
Business Wire - Tue Nov 19, 7:30AM CST
Life Stem Genetics, Inc. (OTCBB:LIFS) (the "Company") is pleased to announce yesterday's closing of its previously announced private placement. The financing is for $1.0 million (the "Private Placement") of 1,000,000 units (each, a "Unit") at a price of $1 per Unit.
Life Stem Genetics Inc names James Vanden Bosch as chief medical stem cell specialist
M2 - Mon Nov 18, 3:01AM CST
Healthcare company Life Stem Genetics Inc (OTCBB:LIFS) reported on Friday the addition of James Vanden Bosch, BHA, as its chief medical stem cell specialist.
Life Stem Genetics Announces James Vanden Bosch as Chief Medical Stem Cell Specialist
Business Wire - Fri Nov 15, 8:37AM CST
Life Stem Genetics, Inc. (LIFS.OTCBB) (the "Company") announces that its Regenerative Specialist, James Vanden Bosch,BHA, has been given the title and responsibility of Chief Medical Stem Cell Specialist at Life Stem Genetics. Mr. Vanden Bosch has been in healthcare for more than a decade and has performed thousands of stem cell treatments on patients. Mr. Vanden Bosch is an accomplished speaker and premier expert in regenerative and stem cell treatments and is an author and publisher of articles to major Medical News Journals on subjects of Orthopedics, Autoimmune, and Neurological conditions.
Life Stem Genetics Announces LOI with Stem Cell Therapy Clinic in Dhaka, Bangladesh
Business Wire - Wed Nov 13, 7:30AM CST
Life Stem Genetics, Inc. (OTCBB:LIFS) (the"Company") announces the signing of a Letter of Intent ("LOI") between Life Stem Genetics, Inc. and Dr. Iqram Rahman ("IR") in Dhaka, Bangladesh.
Detailed Coverage on NVLX, PGLO, LIFS and DROP
ACCESSWIRE - Wed Nov 13, 1:02AM CST
Nuvilex, Inc. (OTC:NVLX), Pan Global Corp. (OTCGLO), Life Stem Genetics Inc. (OTC:LIFS) and Fuse Science, Inc. (OTCROP) have been added to our coverage list.
Life Stem Genetics Announces LOI with a Chain of Health Clinics across Canada
Business Wire - Thu Nov 07, 7:30AM CST
Life Stem Genetics, Inc. (OTCBB:LIFS) announces the signing of a Letter of Intent ("LOI") between Life Stem Genetics, Inc. and a soon to be disclosed health and wellness chain in Canada ("Company"). The announcement of the organization is set to take place in approximately 10 days upon signing of the definitive agreement.
Exclusive Coverage on LIFS, VELT, FVRG and NVGC
ACCESSWIRE - Thu Nov 07, 5:35AM CST
Life Stem Genetics Inc. (OTC: LIFS), Velti Plc (NASDAQ: VELT), ForeverGreen Worldwide Corp. (OTC: FVRG) and Nevada Gold Corp (OTC: NVGC) have been added to our watch list.
Life Stem Genetics Inc names Dr. Rostamkalaee to Executive Advisory Board
M2 - Tue Nov 05, 4:02AM CST
Healthcare company Life Stem Genetics Inc (OTC BB:LIFS) revealed on Monday the addition of Dr. Shirin Rostamkalaee to its newly expanded Executive Advisory Board.
Life Stem Genetics Adds Dr. Rostamkalaee to Enhance Its Executive Advisory Board
Business Wire - Mon Nov 04, 7:30AM CST
Life Stem Genetics, Inc. (OTCBB: LIFS), an emerging innovator in the advancement of Adult Stem Cell therapy, today announced that it has added Dr. Shirin Rostamkalaee, an expert on wound healing, bone grafting, and reconstructive surgery (broad areas with immense applications for Adult Stem Cell ("ASC") therapies) to its newly expanded Executive Advisory Board. The addition of Dr. Rostamkalaee follows the recent appointments of Matthew Sullivan, COO of global health products company Asana International, and Shahab Bakhtyar, an independent medical business consultant with extensive global experience, to the company's Executive Advisory Board.
Life Stem Genetics Strengthens Its Executive Advisory Board by Adding MBAs Matthew Sullivan and Shahab Bakhtyar
Business Wire - Mon Oct 28, 8:00AM CDT
Life Stem Genetics Inc., an emerging innovator in the advancement of Adult Stem Cell therapy, is pleased to announce that Matthew Sullivan, COO of global heath products company Asana International, and Shahab Bakhtyar, an independent medical business consultant with global experience, have joined Life Stem's Executive Advisory Board.
Life Stem Genetics is Pleased to Announce That It Has Completed the First $500,000 Private Placement of the Recently Announced $1mm Private Placement
Business Wire - Tue Oct 22, 8:30AM CDT
Life Stem Genetics (OTCBB:LIFS) is pleased to announce that it has completed and received the first $500,000 of the recently announced $1mm Private Placement. Our company is very happy to receive the first half of our recent private placement and hopes to close the additional $500,000 in the coming weeks.
Life Stem Genetics Has New Stock Symbol and New Financing Commitment
Business Wire - Sat Oct 19, 11:47AM CDT
Life Stem Genetics Inc. (the "Company"), an emerging innovator in the advancement of Adult Stem Cell therapy announces that the Company's new stock symbol, LIFS, is now active.
Life Stem Genetics has new stock symbol and new financing commitment
Filing Services Canada - Sat Oct 19, 11:47AM CDT
Life Stem Genetics Inc. (LIFS - OTCBB), (the "Company"), an emerging innovator in the advancement of Adult Stem Cell therapy announces that the Company's new stock symbol, LIFS, is now active.
Solace Therapeutics Adds New Member to Board of Directors
Business Wire - Tue Sep 17, 9:00AM CDT
Solace Therapeutics, a venture capital funded medical technology company focusing on treating stress urinary incontinence (SUI), announced today that Stacy Enxing Seng has joined the Board of Directors. She serves on the board alongside Ryan Drant, General Partner with New Enterprise Associates (NEA); Ali Behbahani MD, Principal at NEA; John McDonough, CEO at T2 Biosystems; and Kevin G. Connors, founding partner of Spray Venture Partners.